Can Your Breath Predict Lung Cancer Treatment Success? The Role of Nitric Oxide
"A new look at an old friend: How measuring exhaled nitric oxide could help personalize lung cancer therapy and track treatment response."
Lung cancer remains a formidable challenge, being the leading cause of cancer-related deaths worldwide. While treatments have advanced, predicting how a patient will respond to therapy remains a critical area of research. Recent studies have begun to investigate the potential of exhaled nitric oxide (NO) as a biomarker, offering a non-invasive way to monitor inflammation and treatment response in lung cancer patients.
Nitric oxide, a molecule naturally produced in the body, plays a crucial role in various biological processes, including inflammation. In the context of lung cancer, NO levels can indicate the degree of airway inflammation and oxidative stress, both of which are influenced by the tumor itself and the body's response to treatment. Researchers have been exploring whether changes in exhaled NO levels can serve as an early indicator of treatment effectiveness and disease progression.
This article will delve into the findings of a study that examined the relationship between exhaled NO levels and chemotherapy response in lung cancer patients. By understanding how NO levels change during treatment, we can gain valuable insights into the inflammatory processes associated with the disease and potentially personalize treatment strategies for better outcomes. This approach offers a promising avenue for improving lung cancer management and patient care.
Nitric Oxide as an Inflammation Marker
Nitric oxide (NO) is described as a marker of airway inflammation. The source also identifies it as an indirect general indicator of inflammation and oxidative stress. This makes exhaled alveolar nitrogen oxide relevant to research on lung cancer and respiratory biology.
Measuring Exhaled and Blood NO
Research has examined the fraction of exhaled nitric oxide (FeNO) and blood NO in lung cancer patients and control subjects. Measurements have been compared at different time points, including before and after therapy. Exhaled nitric oxide can be measured non-invasively, while alveolar nitric oxide concentration (CaNO) has been proposed as a marker of distal airway inflammation; however, its value in non-small cell lung cancer (NSCLC) remains unknown. A 2021 review described extracting these data through a comprehensive database search conducted by two investigators.
From Discovery to Cancer Research
A historical review describes the development of mammalian nitric oxide research as a trilinear convergence occurring between 1986 and 1988. The history includes earlier work on human and nitrogen oxide interactions, including attempts to study lung oxygen by expiration and inhalation of nitrous oxide. Nitric oxide was later identified as the long-sought endothelium-derived relaxing factor (EDRF), a discovery associated with Nobel Laureate Dr. Lou Ignarro. At MIT, Professor James Fox, Dr. Susan Erdman, and the late Professor David Schauer studied nitric oxide and related species in mouse models of inflammatory bowel disease and cancer using transgenic mice.
Nitric Oxide: A Window into Lung Cancer Treatment Response
A recent study investigated how exhaled nitric oxide (NO) levels change in lung cancer patients undergoing chemotherapy. The study involved 42 patients diagnosed with early-stage lung cancer. Researchers measured NO levels in their exhaled breath before and after three cycles of chemotherapy, while also monitoring inflammatory markers and lung function.
- NO Levels and C-Reactive Protein (CRP): A direct relationship was observed between NO levels and CRP, a key marker of inflammation, both before and after chemotherapy.
- NO Levels and Monocytes: A notable correlation was found between exhaled NO levels and monocyte counts (P < 0.003, r = 0.49), a type of white blood cell involved in inflammatory responses, regardless of whether it was before or after chemotherapy.
Nanostructures and NSCLC Drug Resistance
A 2018 study investigated the construction and biological evaluation of different self-assembled nanoarchitectures of FZU-03,010. The work focused on NSCLC and multidrug resistance, using biological evaluation to examine these nanoarchitectures. Its abstract identifies chemotherapy as a promising therapeutic method for NSCLC while describing multidrug resistance as the greatest obstacle to efficient drug delivery and successful chemotherapy.
An Unconfirmed Inflammatory Link
Exhaled nitric oxide has been discussed in relation to airway inflammation and eosinophils in patients with lung cancer. However, the cited study reports that the expected correlation between NO and eosinophils was not demonstrated. This finding limits how confidently exhaled NO can be interpreted as a proxy for eosinophilic inflammation in that study.
Treatment Tradeoffs and NO Targeting
A systematic review examined FeNO or blood NO across lung cancer patients and control subjects, as well as before and after therapy. In NSCLC treatment, a separate review reports that combining immuno-oncotherapy (IO) with chemotherapy (CT) has been superior to IO or CT alone for patient survival. That benefit creates a preference-sensitive choice between more aggressive treatment with greater negative effects on quality of life and available alternatives. Targeting nitric oxide synthase (NOS) in the tumor microenvironment has also gained interest as a strategy intended to reduce metastasis, target chemoresistant and self-renewing cancer stem cells, and improve systemic chemo- or radiotherapy.
The Future of Lung Cancer Treatment: Personalized Approaches
The study underscores the potential of exhaled NO as a valuable tool for monitoring treatment response and personalizing lung cancer therapy. By tracking changes in NO levels, clinicians may be able to:
What the Evidence Supports
A 2021 systematic review collected studies measuring FeNO or blood NO in different populations and at different treatment time points. Its method used a comprehensive database search, data extraction by two investigators, and a random-effects model to analyze differences in FeNO. Another clinical study concluded that exhaled nitric oxide levels were significantly increased in patients with lung cancer, potentially confirming an airway inflammation process. Together, these sources support NO as a research marker while leaving its clinical interpretation dependent on the evidence available.
Toward More Controlled NO Therapies
A 2026 bibliometric analysis identifies research trends and hotspots involving nitric oxide donors in cancer. It describes NO as a critical signaling messenger in normal physiology and notes that its complex roles in cancer biology have stimulated efforts to make anti-tumor effects more controllable and specific. A 2026 briefing likewise describes NO as important for blood flow, neurotransmission, and immune regulation while emphasizing its dual role in cancer. A review of inhaled nitric oxide therapy examines its historical evolution, mechanisms, clinical applications, challenges, and future directions.
<ul> <li><b>Assess Treatment Effectiveness:</b> Early reductions in NO levels could indicate a positive response to chemotherapy, allowing for timely adjustments to treatment plans if needed.</li> <li><b>Identify Inflammatory Responses:</b> Monitoring NO levels can help identify patients with heightened airway inflammation, enabling targeted interventions to manage this aspect of the disease.</li> <li><b>Personalize Treatment Strategies:</b> NO measurements could contribute to a more individualized approach to lung cancer treatment, tailoring therapies based on a patient's specific inflammatory profile.</li> </ul>
While further research is needed to validate these findings and explore the full potential of NO as a biomarker, this study offers a promising glimpse into the future of lung cancer management. Non-invasive monitoring of exhaled NO could pave the way for more effective and personalized treatment strategies, ultimately improving outcomes for patients with this challenging disease.